Joseph Drumm, DO
Psychiatry · Jackson, MINPI 1619262680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,400 of the $12,646 with a category attached, or 82.2%. AbbVie accounts for 89.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $10,464 and has fallen 99.0% since, to $106 in 2025. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $133.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Supernus Pharmaceuticals, Inc.$333
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$266
- Johnson & Johnson$180
- Otsuka America Pharmaceutical, Inc.$144
- Ironshore Pharmaceuticals Inc.$102
- plus $267 from 7 others
What the payments were for
- Speaking & faculty fees$10,40082%
- Travel & lodging$5554%
- Food & beverage$1,63613%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $11,354 |
| Supernus Pharmaceuticals, Inc. | 31 | $333 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $266 |
| Johnson & Johnson | 6 | $180 |
| Otsuka America Pharmaceutical, Inc. | 7 | $144 |
| Ironshore Pharmaceuticals Inc. | 4 | $102 |
| Lundbeck LLC | 4 | $86 |
| Neurocrine Biosciences, Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$10,879
- INVEGA SUSTENNA$103
- INVEGA TRINZA$103
How this compares
$12,646 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 13 | $716 |
| Quetiapine Fumarate | 42 | $483 |
| Gabapentin | 22 | $345 |
| Olanzapine | 18 | $309 |
| Prazosin Hcl | 11 | $275 |
| Trazodone Hcl | 15 | $188 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $104 |
| Lamotrigine | 16 | $102 |
| Bupropion XlBupropion Hcl | 17 | $97 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Jackson
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
- Samuel WedesLivonia$158K
- Arash JavanbakhtDetroit$102K
- Theodore RuzaWest Bloomfield$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.